1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6DE5725301ABDC467652583DE0025E54C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/enhancing-msl-interactions-non-us-healthcare-practitioners?opendocument
18
19opendocument
20100.25.43.188
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Medical Science Liaison

Enhancing MSL Interactions with Non-US Healthcare Practitioners

ID: POP-304


Features:

3 Info Graphics

12 Data Graphics

100 Metrics

6 Narratives


Pages: 22


Published: 2019


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Globally, pharmaceutical field medical specialists such as Medical Science Liaisons (MSLs) serve as a key conduit between pharma and healthcare practitioners (HCPs). However, field team interaction practices differ markedly when comparing US and the regions outside United States.

MSL interactions with non-US HCPs continues to evolve as pharmaceutical companies are re-evaluating and updating their guidelines for scientific interactions.

Best Practices, LLC conducted this benchmarking research to gather insights on current MSL practices for HCP interactions outside the US. This report establishes benchmarks around HCP interactions and proactive disease presentations, unsolicited requests on clinical data and off-label uses, and group HCP presentations. This report also delivers insights on the frequency, format, content and evaluators for recertification of MSLs.

Global or non-US pharmaceutical field medical team leadership can refer to this research to compare their approach to MSL interactions with current industry practices.

Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Alfasigma; Allergan; Bayer; Boehringer Ingelheim; Janssen; Merck; Pfizer; Sanofi; Vifor Pharma

Study Snapshot

Best Practices, LLC engaged nine medical affairs leaders based outside the US from 9 leading biopharmaceutical companies in this research through a benchmarking survey. Fifty-six percent of the respondents serve at the Director level; and 22% serve as Heads.

Key topics covered in this report include:

  • MSL Interactions with HCP Groups
  • MSL Involvement in Proactive Disease State Education
  • MSL Engagement with KOLs in Early Development Stage
  • Best Practices for MSL Interactions Outside the US
  • Re-certification of MSLs


Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Proactive Disease State Education: MSLs outside the US typically do proactive disease state education 1 year prior to launch; 33% of respondents have no restrictions on timing for presentations.

  • Off-Label Exchanges: Forty-four percent of participants allow off-label exchanges after an unsolicited request and another 22% allow it if requested by HCPs. The remaining 33% do not allow.

Table of Contents

1.
Executive Summarypgs. 3-7
Benchmark Class
MSL Interactions Overview
2.
MSL Interactions with Non-US HCPspgs. 8-13
3.
MSL Involvement in Proactive Disease State Educationpg. 14
4.
MSL Engagement with KOLs in Early Development Stagepg. 15
5.
Best Practices for MSL Interactionspg. 16
6.
Recertification of MSLspgs. 17-18
Format for Testing
Subject Matter/ Content for Testing
Evaluators for Recertification Testing
7.
Appendixpgs. 19-21

    List of Charts & Exhibits

    I. MSL Interactions with Non-US HCPs

    • Permission given to MSLs to present standard of care treatment information in proactive disease presentation
    • Permission given to MSLs to leave behind slides from a disease state presentation on an HCP’s request
    • Permission given to MSLs to present clinical data on an unapproved product upon receiving an unsolicited request
    • Permission given to MSLs to present off-label clinical information of an approved product in a group HCP setting, upon receiving an unsolicited request
    • Permission given to MSLs to respond to off-label questions during a presentation in a group HCP setting
    • Development stage at which MSLs are allowed to do proactive disease state (non-product) education
    • Timing of MSL engagement of KOLs in the development process
    • Best practices for MSL interactions with non-US HCPs

    II. MSL Recertification

    • Frequency, format, content and evaluators for recertification of MSLs